Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated

KIORA PHARMACEUTICALS INC

Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.
Resignation not due to any disagreement with company's operations, policies, or practices.
Company has initiated a search for Daniels' successor; CEO thanked Daniels for his contributions.
Kiora continues enrollment in KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials.
Safety reviews cleared for KIO-301 50µg and 100µg dose cohorts; KIO-104 enrollment ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.